Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trial
Open Access
- 30 April 2008
- journal article
- clinical trial
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 58 (4), 625-631
- https://doi.org/10.1016/j.jaad.2007.12.035
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- The Risk of Mortality in Patients With PsoriasisArchives of Dermatology, 2007
- Prevalence of cardiovascular risk factors in patients with psoriasisJournal of the American Academy of Dermatology, 2006
- Effects of Curcumin on Tumour Necrosis Factor‐α and Interleukin‐6 in the Late Phase of Experimental Acute PancreatitisJournal of Veterinary Medicine Series A, 2006
- Prevalence and Treatment of Psoriasis in the United KingdomArchives of Dermatology, 2005
- A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasisJournal of the American Academy of Dermatology, 2004
- Curcumin inhibits phorbol ester-induced expression of cyclooxygenase-2 in mouse skin through suppression of extracellular signal-regulated kinase activity and NF- B activationCarcinogenesis: Integrative Cancer Research, 2003
- Curcumin Suppresses Activation of NF-κB and AP-1 Induced by Phorbol Ester in Cultured Human Promyelocytic Leukemia CellsBMB Reports, 2002
- Drug‐induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parametersBritish Journal of Dermatology, 2000
- Skindex, a Quality-of-Life Measure for Patients with Skin Disease: Reliability, Validity, and ResponsivenessJournal of Investigative Dermatology, 1996
- Pharmacology ofCurcuma longaPlanta Medica, 1991